Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant interferon alpha-1b
- Development stage
- Unknown
- Lead developer
- Shenzhen Kexing Biopharm
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular
01
Overview
Recombinant interferon alpha-1b is a type I interferon cytokine that possesses antiviral, antiproliferative, and immunomodulatory activities. It is a recombinant protein typically produced in *Escherichia coli* that mimics the naturally occurring human interferon alpha-1b subtype. The drug exerts its biological effects by binding to the heterodimeric Type I interferon receptor (IFNAR), which consists of IFNAR1 and IFNAR2 subunits. This binding activates the JAK-STAT signaling pathway, leading to the nuclear translocation of transcription factors and the subsequent expression of interferon-stimulated genes (ISGs). In the context of oncology, specifically clear cell renal cell carcinoma (ccRCC), it is utilized to enhance the host's immune response against tumor cells and directly inhibit tumor cell growth. The Case Comprehensive Cancer Center sponsored a Phase II clinical trial (NCT00003810) to evaluate the objective response rate of this specific interferon subtype in patients with metastatic clear cell renal carcinoma.
- Brand names
- SinogenHapgen
- Other names
- Interferon alpha-1brecombinant human interferon alpha-1b
02
Targets
IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR1 (Interferon alpha/beta receptor 1)
Beyond the preview
Go deeper on recombinant interferon alpha-1b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant interferon alpha-1b.